卡培他滨与替吉奥治疗晚期大肠癌疗效比较

The comparative effect of capecitabine and tegafur/gimeracil/oteracil（S-1） on advanced colorectal cancer

目的比较卡培他滨与替吉奥治疗晚期大肠癌的临床疗效。方法106例晚期大肠癌患者按数字表法随机分为卡培他滨组（52例）和替吉奥组（54例），观察比较两组临床效果和化疗不良反应。结果化疗1个疗程后，卡培他滨组完全缓解3例、部分缓解19例、病情稳定15例、病情进展15例、有效率42．3％、病情控制率71．2％，替吉奥组分别为5例、21例、19例、9例、48．1％、83．3％，两组有效率及疾病控制率差异均无统计学意义（P〉0．05）。两组化疗不良反应发生率和生存时间差异均无统计学意义（均P〉0．05）。结论卡培他滨与替吉奥治疗晚期大肠癌同样安全、有效。

Objective To test comparative effect of capecitabine and S-1 （Tegafur/gimeracil/oteracil）on advanced colorectal eancer. Methods 106 cases of advanced colorectal cancer in our hospital ontology were eoUeet- ed and randomly divided into 2 groups ： capecitabine group （ 52 cases） and S-1 group （ 54 cases）. The chemotherapy effect and adverse effect of 2 groups were collected. Results After one treatment period,3 cases of complete remis- sion, 19 cases of partial remission, 15 eases of stable disease, 15 cases of disease progression,efficient rate of 42.3% and control rate of 71.2% were observed in eapeeitabine group. 5 eases of complete remission,21eases of partial re- mission,19 cases of stable disease,9 cases of disease progression and efficient rate of 48.1% and control rate of 83.3% were observed in S-1 group. There were no significant differenees in efficient rate, control rate adverse effect rate and survival time between 2 groups （ P 〉 0.05 ）. Conclusion Capeeitabine and S-1 are both safe and effective in treatment of advanced coloreetal cancer.